Advances in Diabetic Ischemic Heart Failure
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 30
Special Issue Editor
Special Issue Information
Dear Colleagues,
In patients with diabetes mellitus, rapid progression of atherosclerosis can lead to spectrum of cardiovascular diseases including chronic and acute forms of coronary artery disease, as well as ischemic cardiomyopathy and heart failure. Over the last 5–10 years we have witnessed on one of the major advances in the field of cardiology regarding new treatment modalities in patients with heart failure. In fact, application of new glucose-lowering drugs—sodium/glucose-co-transporter-2 (SGLT2) inhibitors and glucagon-like peptuide-1 (GLP1) receptor agonists—has further promoted interest in the management of patients with diabetes, ischemic heart disease and heart failure. Determining the best molecular diagnostic, therapeutic and revascularization strategy with diabetes, ischemic heart disease and heart failure remains one of the most challenging issues in current cardiology treatment.
In this special issue, we shall discuss different aspects of ischemic cardiomyopathy with diabetes starting with pathophysiological mechanism for the progression of the disease to heart failure, followed by contemporary diagnostic and therapeutic modalities, up to revascularization options and strategy.
Prof. Dr. Branko Beleslin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes
- ischemic cardiomyopathy
- pathophysiology
- diagnostics
- therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
